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Background: Observational cohort study to assess the association between adherence to oral 5-aminosalicylates
(5-ASAs) and all-cause costs and health care utilization among patients with active ulcerative colitis (UC) in the
United States.
Methods: Retrospective analysis of insurance claims from June 1997 to August 2006 in the LifeLink Database.
Patient criteria: aged 18 or older with one or more claim(s) between June 1997 and August 2005 for a UC diagnosis
and at least one oral 5-ASA prescription on or after the first observed UC diagnosis; continuous enrollment for at
least 6 months prior to and 12 months following 5-ASA initiation (index date). As a proxy for active disease, patients
needed to have at least two UC-specific non-pharmacy claims, at least 30 days of 5-ASA treatment and at least one
corticosteroid prescription within the 12-month post-index period. Cumulative exposure to oral 5-ASAs over the
12-month period was calculated using the medication possession ratio (MPR). Patients with an MPR of at least 0.80
were classified as adherent. All-cause medical and pharmacy resource utilization and costs were computed over
the 12-month post-index period and compared between adherent and nonadherent patients.
Results: 1,693 UC patients met study inclusion criteria: 72% were nonadherent to 5-ASA treatment (n = 1,217) and
28% were adherent (n = 476) in the 12-month study period. Compared with nonadherent patients, adherent
patients had 31% fewer hospitalizations (P= 0.0025) and 34% fewer emergency department admissions (P= 0.0016).
Adherent patients had 25% more pharmacy prescriptions overall (P <0.0001) and 71% more UC-related pharmacy
prescriptions (P <0.0001) than did nonadherent patients. Total all-cause health care utilization was 1.13 times higher
for adherent patients than for nonadherent patients (P= 0.0002). After adjusting for covariates, total all-cause costs
were 29% higher for nonadherent patients than for adherent patients (mean [95% confidence interval]: $13,465
[$13,094, $13,835] vs $17,339 [$17,033, $17,645]).
Conclusions: Approximately three-quarters of patients with active UC were not adherent with their prescribed
doses of oral 5-ASA. Nonadherence was associated with higher total all-cause costs. The key driver of decreased
costs among adherent patients was inpatient hospitalizations, which more than offset these patients’ expected
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Ulcerative colitis (UC) is a chronic inflammatory bowel
disease characterized by mucosal inflammation in the
colon. Usually, UC affects individuals between 15 and
40 years of age, although it can be found among patients
of any age. The annual incidence rate of UC in the
United States (US) is estimated to be eight cases per
100,000 individuals[1]. UC is an expensive medical
condition, imposing a significant burden on patients,
employers, and third-party payers. In 1998, the total
direct cost of UC in the US was estimated to be $388
million, with pharmacotherapy contributing to $138
million of these costs and inpatient hospitalizations
accounting for 50% of the total expenditure [2]. The
reported annual direct economic burden per patient varies
significantly in the literature. Kappleman et al., [3] using
an administrative claims data set, found the mean annual
direct health care cost of UC to be $5,066 per patient per
year (in 2004 US dollars); 38% of costs were attributable
to hospitalization, 35% to outpatient care, and 27% to
pharmaceutical claims. Another study found the mean an-
nual all-cause total health care costs for patients with UC
to be $13,233 (in 2005 US dollars), 44% of which consisted
of inpatient hospitalization costs [4].
Because the underlying cause is usually unclear, treat-
ment of UC is typically aimed at first controlling inflam-
mation and symptoms (i.e., inducing remission) and
then maintaining that control (i.e., maintaining remis-
sion) [5,6]. According to the American College of
Gastroenterology practice guidelines for adult UC
patients, [7] oral therapy with 5-aminosalicylic acids (5-
ASAs) such as mesalamine, balsalazide, sulfasalazine,
and olsalazine is typically used as first-line therapy for
mild to moderate UC. Therapy with 5-ASAs has been
shown to be efficacious and well tolerated both for the
treatment of active disease [6] and for the maintenance
of remission [5]. However, some of the current oral for-
mulations of 5-ASAs are inconvenient for patients be-
cause patients require multiple doses per day and/or
multiple tablets per dose. In a chronic disease such as
UC, where patients may be on long-term or lifelong
medication support, such treatment imposes a signifi-
cant burden on UC patients, and potentially can reduce
quality of life and can negatively impact adherence to
the treatment. Previous studies have found that, for the
patient being treated for a chronic condition, nonadher-
ence to the treatment can cause a reduction in treatment
benefits, [8] can bias clinician assessment of the treat-
ment’s effectiveness, [9] and can lead to poorer disease
prognosis [10]. Further, nonadherence to treatment for
chronic conditions has been linked to increased health
care utilization [11].
Previous studies have demonstrated that adherence and
persistence with 5-ASAs in patients with UC is usuallylow. In a study using the IMS LifeLink™ database (IMS
Health Incorporated, Danbury, Connecticut; formerly
PHARMetricsW Inc.), Yen et al. [12] found that only 15.2%
of patients were adherent to oral 5-ASA therapy in the
first year following treatment initiation. Another study
found that among patients receiving pharmacotherapy for
gastrointestinal conditions, only 22% were persistent with
their oral 5-ASA therapy [13]. In a review article on ad-
herence to UC therapy, Kane[14] concluded that failure
to adhere to the prescribed UC regimen is associated
with an increased risk of symptomatic relapse, greater
risk of disease progression (e.g., development of colorec-
tal cancer), decreased quality of life, and higher overall
cost of care. Improving medication adherence in UC
patients therefore could lead to reduced health care costs
and improved outcomes.
Although the significant economic burden of UC and
the low rate of adherence with UC medications has been
well established in the literature, the impact of adher-
ence with oral 5-ASA therapies on health care utilization
and associated costs among patients with active UC
has not been widely investigated. In this study, we ana-
lyzed administrative claims data from a large managed
care population in the US to examine the impact of oral
5-ASA adherence on all-cause health care utilization
and costs (both medical and pharmacy) among adult
patients with evidence of active UC.
Methods
Data source
Data were extracted from the IMS LifeLink database. At
the time of our study, the database included enrollment,
medical, and prescription information from 75 managed
care health plans covering more than 40 million unique
patients and over 2 billion health care transactions in
the US from 1997 to 2006. The LifeLink database com-
prises longitudinal insurance claims from managed care
organizations in all four US geographic regions and has
an age and gender distribution representative of national
managed care enrollment [15].
The LifeLink database consists of patient demograph-
ics, institutional and professional medical claims for in-
patient and outpatient services, outpatient prescription
drug claims, and periods of health plan enrollment
(start and stop dates). Each medical claim includes date
and place of service (e.g., inpatient, outpatient, emer-
gency department [ER]), four International Classifica-
tion of Diseases, 9th Revision, Clinical Modification
(ICD-9-CM) diagnosis codes, and cost data in the form
of managed care reimbursements (actual paid amount)
for medical services and prescription drugs utilized.
Medical claims in the database also include Health Care
Financing Administration Common Procedure Coding
System and Current Procedural Terminology Version 4
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as well as information on provider specialty. Prescription
drug claims include the National Drug Code, brand and
generic name, quantity dispensed, days’ supply, strength,
and paid amount for prescriptions obtained through out-
patient or retail pharmacies. Data are tracked longitudin-
ally within patients via de-identified and unique patient
numbers.
Due to the de-identified nature of the LifeLink data-
base and the fact that no new data were gathered, our
study was granted exemption from the Institutional
Review Board at RTI International, which holds a
Federal-Wide Assurance (#3331) from the US Depart-
ment of Health and Human Services’ Office for Human
Research Protections; RTI Health Solutions, the organi-
zation that conducted this study, is a business unit of
RTI International.
Study population
Our study sample was defined by selecting patients from
the LifeLink database (1997–2006) who had any primary
or nonprimary diagnosis of UC (ICD-9-CM 556.xx)
between June 1997 and August 2005 and at least one
prescription claim for an oral 5-ASA on or after the date
of each patient’s first observed UC diagnosis. For each
patient identified, an index date was defined as the date
of the first observed prescription for an oral 5-ASA. To
ensure that each patient’s index date was a reasonable
marker for oral 5-ASA therapy initiation (or re-initiation
after an extended break), patients included in the study
sample were required to have at least 6 months of con-
tinuous health plan enrollment prior to their index date,
with no evidence of 5-ASA use during that time frame.
Similarly, to ensure that any observed lack of health
care events following 5-ASA therapy initiation was due
to a true lack of medical activity and not cessation of
insurance, patients included in the study sample were
required to have at least 12 months of medical and phar-
macy benefits eligibility following their index date. Each
patient also was required to have a minimum duration
of 30 days of 5-ASA therapy during the 12-month fol-
low-up period. Finally, patients were required to have at
least one period of active disease during follow-up,
which was identified by proxy as evidence of of at least
two UC-specific non-pharmacy claims and at least one
corticosteroid prescription within the 12-month post-
index date period. Patients with Crohn’s disease (ICD-9-
CM 555.xx) were excluded from the study.
Study measures
Baseline patient characteristics
Patient characteristics that were measured at the index
date included age, gender, geographic region, insur-
ance payer type (e.g., commercial, self, governmentsponsored), and health plan type (e.g., health mainten-
ance organization, preferred provider organization).
To assess overall comorbidity burden prior to 5-ASA
initiation, a Charlson Comorbidity Index (CCI) score,
with Deyo adaptation for claims data, was calculated
for each patient [16,17]. The CCI includes 17 categor-
ies of comorbidities, as defined by ICD-9-CM diagno-
sis codes, with associated weights corresponding to
the severity of the comorbid condition of interest. A
higher CCI score represents a higher overall comor-
bidity burden. A single CCI score was calculated for
each patient on the basis of the presence of the corre-
sponding diagnosis during the 6-month period prior
to the index date.
Adherence measure
Oral 5-ASA adherence was measured using the medica-
tion possession ratio (MPR). A systematic literature re-
view [18] found the MPR to be the most widely adopted
measure (57% of all studies) in published claims-based
analyses of medication adherence. MPR is defined as the
proportion of days within an observation period covered
by the total days’ supply for a particular study drug
within the observation period. The observation period
used in the MPR calculation can be either a fixed num-
ber of days within a follow-up period (i.e., 365 days fol-
lowing treatment initiation) or the number of days
between the first dispense date and end of the days’ sup-
ply of the last refill for the study therapy of interest [18].
Oral 5-ASAs are intended to be used continuously and
long-term (i.e., chronically) in order to maintain remis-
sion. Therefore, adherence for these medications must
be evaluated with respect to drug exposure or supply
coverage over a longer, fixed period. In this context,
early discontinuation would count against MPR, and the
use of a denominator that is defined as days between the
first dispense and last prescription dates does not cap-
ture the negative adherence effect of complete therapy
discontinuation.
To account for discontinuation, we defined the
denominator of the MPR formula as a fixed value
of 365 days (i.e., total days in the fixed, post-index fol-
low-up period) so that those patients who discontinued
5-ASA therapy completely before the end of the follow-
up period would correctly have a lower MPR. The fol-
lowing formula was used:
MPR ¼ Total oral 5ASA days supplied
in 12month followup period  365 days:
Note that changes in medication dose had no impact
on how refill adherence was calculated. A patient who
had a dose titration upward or downward would have
the same adherence as a patient who remained on the
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scription refill patterns. Mean MPR and adherence rates
were calculated for the overall 5-ASA class, not separ-
ately by individual 5-ASA medications. For example, if
a patient switched from mesalamine to sulfasalazine,
the patient’s adherence was measured as cumulative
exposure to both 5-ASA drugs. Switching between two
oral 5-ASA classes therefore did not impact the calcula-
tion of MPR.
Patients with an MPR of less than 0.8 (i.e., less than
80% adherence) were classified as nonadherent. The 80%
threshold for identifying adherence and nonadherence to
chronic-use medications has been previously validated
[19] and has been used in numerous previously con-
ducted adherence studies [20-22]. To assess the distribu-
tion of MPR among nonadherent patients, patients with
an MPR of less than 0.8 were further stratified into four
groups: MPR 0.0 to 0.19, 0.20 to 0.39, 0.40 to 0.59, and
0.60 to 0.79.
All-cause health care utilization and costs
Total health care services utilized and associated costs
during the 12-month period following initiation of 5-
ASA therapy were calculated. Costs were calculated
from the perspective of the third-party payer and repre-
sented actual reimbursed amounts for each service
rendered. Our cost data therefore did not take into
account patient copayments, co-insurance, and other
out-of-pocket expenses. All-cause health care utilization
and costs were compared between the group of patients
who were adherent to 5-ASA therapy and the group of
patients who were not. Differences in baseline demo-
graphic characteristics (age, gender, geographic region,
health plan type, and payer type) and comorbidity bur-
den (CCI scores) were controlled for when calculating
total adjusted all-cause health care utilization. We did
not adjust for baseline, i.e., pre-index, health care costs.
The adjusted all-cause health care costs were stratified
by the following cost sectors: inpatient admissions, ER
visits, outpatient office visits, other non-office outpatient/
ancillary visits (e.g., day procedures), and prescription
drugs (UC related and non-UC related). UC-related pre-
scriptions were defined as all prescriptions for oral
and rectal 5-ASAs, corticosteroids, biologics (infliximab),
immunosuppressants, and select antibiotics (ciprofloxacin
and metronidazole). All cost estimates were adjusted to
2010 US dollars, using the medical care component of
the US Consumer Price Index [23].
Statistical analyses
All analyses were carried out using SAS (Version 9.1.3)
statistical software package (SAS Institute, Inc, Cary,
North Carolina). Descriptive analyses entailed the tabular
display of the mean value, standard deviation, median,and range of continuous variables of interest and the fre-
quency distribution of categorical variables of interest.
For descriptive analyses, chi-squared tests for dicho-
tomous variables and paired t-tests for continuous varia-
bles were used to assess statistical differences in the
outcomes of interest across all patients, stratified by
adherence status.
Multivariable regression analyses were performed to as-
sess differences in all-cause health care utilization and
costs between 5-ASA adherent and nonadherent UC
patients after controlling for patient demographic charac-
teristics and baseline comorbidity burden. The type of
multivariable model estimated depended on the nature of
the outcome that was assessed. For count data, outcomes
such as number of inpatient admissions and outpatient
office visits were used. Poisson regression models were
used to compare the rate of resource utilization between
the two cohorts. These models provided incidence rate
ratios (IRRs), which were obtained by exponentiating the
coefficients from each model estimated. The magnitude of
the IRR describes the incidence rate of utilization (e.g.,
number of hospitalizations) for patients adherent to
5-ASA therapy as a multiple of the utilization incidence
rate among nonadherent patients. For example, an esti-
mated IRR of 0.5 for a binary covariate defining nonadher-
ence (i.e., 1 = adherent, 0 =nonadherent) suggests that
patients who were adherent with 5-ASA therapy had 50%
fewer hospitalizations than patients who were nonadherent
to 5-ASA therapy.
To assess differences in health care costs between the
two study cohorts, a multivariable generalized linear
model (GLM) framework was used, with a log-link func-
tion and a gamma distribution for the error term to
resolve the issue of skewed cost distribution often
reported in health care cost data. In comparison with or-
dinary linear regression involving log-transformed cost
data, the GLM methodology offers several advantages,
primarily because it estimates covariate-adjusted pre-
dicted mean costs on a dollar scale, which can then be
compared using Student’s t-test [24-26]. The GLM
methodology avoids potential biases resulting from the
Duan smearing method for retransforming the predicted
coefficient from log-transformed cost data [26-28].
Results
We identified 99,842 patients in the LifeLink database
who had at least one primary or nonprimary diagnosis
code for UC (ICD-9-CM 556.xx) between June 1997 and
August 2005. Nearly 60% of these patients (n = 57,971)
did not have any pharmacy claims for oral 5-ASA ther-
apy and therefore were excluded. The final study sample
consisted of 1,693 patients who met all study inclusion
and exclusion criteria. Figure 1 provides a detailed break-
down of the sample attrition.
Figure 1 Sample attrition. 5-ASA= 5-aminosalicylate; ICD-9-CM= International Classification of Diseases, 9th Revision, Clinical Modification;
UC= ulcerative colitis.
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Table 1 presents descriptive statistics on various baseline
demographic characteristics of the study sample, overall
and stratified by the adherence status. The mean age
was 42 years for the overall study sample, and there was
equal distribution of male and female patients. Nearly
45% of patients resided in the Midwest, with the
remaining patients equally distributed between the East,
South, and West. Preferred provider organizations and
health maintenance organizations were the most com-
mon types of health plans, covering 40% and 37% of
patients, respectively. The mean CCI score for the over-
all study sample was 1.23.
The majority of UC patients (72%) were nonadherent to
oral 5-ASA therapy (n= 1,217) during the 12-month study
period. Adherent patients were more likely to be male
than were nonadherent patients (55% vs 48%; P=0.0090),
with no difference in average age between the two groups.A slightly larger percentage of patients in the adherent
group resided in the Midwest than did the nonadherent
group (49% vs 43%; P=0.0113). Further, adherent patients
had a greater baseline comorbidity than did non-adherent
patients (CCI score 1.36 vs 1.18; P=0.0378).Adherence measure
Figure 2 presents the overall MPR distribution for oral
5-ASA therapy. Twenty-eight percent of the sample was
adherent to therapy over the 12-month follow-up period,
while 20% of patients had an MPR less than 0.20. The
mean MPR for the overall study sample was 0.54 (range:
0.08-1.00; median = 0.56; data not shown). Among
the adherent group, the mean MPR was 0.90 (range:
0.80-1.00; median = 0.90); and among the nonadherent
group, the mean MPR was 0.40 (range: 0.08-0.79;
median = 0.38).
Table 1 Characteristics of the study population, by 5-ASA adherence status
Characteristic All 5-ASA Initiators Adherence Status P Valuea
Not Adherent Adherent
n % n % n %
n (row%) 1693 100.00 1217 100.00 476 100.00
Gender
Female 840 49.62 628 51.60 212 44.54 0.0090
Male 853 50.38 589 48.40 264 55.46 —
Age
Mean (SD) 42.3 (12.8) 42.4 (12.8) 42.2 (12.9) 0.7675
Median 42 42 43.5
Range (minimum, maximum) (18, 93) (18, 93) (18, 78)
Distribution (years)
18-24 165 9.75 112 9.20 53 11.13 0.2283
25-44 775 45.78 576 47.33 199 41.81 0.0403
45-54 433 25.58 304 24.98 129 27.10 0.3684
55-64 280 16.54 191 15.69 89 18.70 0.1349
65+ 40 2.36 34 2.79 6 1.26 0.0619
Geographic region
East 354 20.91 260 21.36 94 19.75 0.4623
Midwest 759 44.83 528 43.39 231 48.53 0.0113
South 306 18.07 238 19.56 68 14.29 0.0557
West 274 16.18 191 15.69 83 17.44 0.3815
Health plan type
HMO 629 37.15 442 36.32 187 39.29 0.2561
Indemnity 39 2.30 30 2.47 9 1.89 0.4788
POS 261 15.42 181 14.87 80 16.81 0.3218
PPO 681 40.22 505 41.50 176 36.97 0.0881
Unknown 30 1.77 21 1.73 9 1.89 0.8168
Multiple types 53 3.13 38 3.12 15 3.15 0.9756
Payer type
Commercial 1423 84.05 1020 83.81 403 84.66 0.6672
Medicaid 18 1.06 15 1.23 3 0.63 0.2774
Medicare 48 2.84 40 3.29 8 1.68 0.0735
Self-insured 56 3.31 37 3.04 19 3.99 0.3251
Medigap 2 0.12 2 0.16 0 0.00 0.3762
Unknown 144 8.51 101 8.30 43 9.03 0.6262
Multiple types 2 0.12 2 0.16 0 0.00 0.3762
CCI score
Mean (SD) 1.23 (1.60) 1.18 (1.59) 1.36 (1.62) 0.0378
Median 0 0 0
Range (minimum, maximum) (0, 9) (0, 9) (0, 8)
5-ASA = 5-aminosalicylate; CCI = Charlson Comorbidity Index; HMO=health maintenance organization; POS = point of service; PPO=preferred provider
organization; SD = standard deviation.
aChi-square tests for categorical variables, t-tests for continuous variables.
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Figure 2 MPR distribution for overall oral 5-ASA therapy. 5-ASA= 5-aminosalicylate; MPR=medication possession ratio.
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Table 2 presents covariate-adjusted IRRs and correspond-
ing 95% confidence intervals (CIs) from the Poisson re-
gression models. The models were used to assess
differences in the rate of all-cause health care resource
utilization between the adherent and nonadherent patient
cohorts. Adherent patients had approximately 31% (IRR=
0.6928; P=0.0025) fewer hospitalizations and 34% (IRR=
0.6584; P=0.0016) fewer ER admissions than did nonad-
herent patients. Patients who were adherent had 25%
more pharmacy prescriptions overall. Adherent patients
also had 71% more UC-related pharmacy prescriptions
than did nonadherent patients, but the number of
non–UC-related prescriptions did not differ between the
two groups. The total number of all-cause health care vis-
its across all cost sectors (including inpatient, ER, out-
patient, and pharmacy) was 1.13 times higher for adherentTable 2 Association between 5-ASA adherence and all-cause h
5-ASA initiation
Dependant Variable Incident Rat
Number of inpatient admissions 0.692
Number of ER visits 0.658
Number of outpatient office visits 1.000
Number of other outpatient/ ancillary visits 0.930
Number of pharmacy prescriptions 1.250
Number of UC-related pharmacy prescriptions 1.709
Number of non–UC-related pharmacy prescriptions 0.998
Number of non-pharmacy visits 0.960
Number of total visits 1.129
5-ASA = 5-aminosalicylate; ER = emergency department; UC = ulcerative colitis.
aIncident rate ratios are based on Poisson regression models and show utilization a
for age, gender, geographic region, health plan type, payer type, and Charlson Compatients than for nonadherent patients (IRR = 1.1294;
P = 0.0002).
Table 3 presents covariate adjusted predicted mean
all-cause health care costs for adherent and nonadher-
ent patients using GLM models. After adjusting for
baseline demographic characteristics and the CCI score,
the predicted mean all-cause cost per patient for hospi-
talizations was approximately two times higher for
nonadherent patients than it was for adherent patients
(mean [95% CI]: $14,542 [$14,314, $14,770] vs $28,727
[$28,443, $29,010]). The mean total cost of ER visits per
patient was approximately 28% higher in the nonadhe-
rent group than in the adherent group. The mean costs
of UC-related pharmacy prescriptions were more than
two times higher for patients who were adherent than
for those who were not (mean [95% CI]: $3,569 [$3,520,
$3,617] vs $1,718 [$1,703, $1,734]). Total all-causeealth care utilization during 12-month period following
e Ratioa Confidence Interval P Value
8 0.5461 0.8789 0.0025
4 0.5077 0.8538 0.0016
4 0.9200 1.0878 0.9925
6 0.8587 1.0086 0.0798
3 1.1624 1.3448 < .0001
5 1.6258 1.7974 < .0001
9 0.8862 1.1258 0.9852
5 0.8937 1.0322 0.2725
4 1.0595 1.2039 0.0002
mong adherent patients compared to nonadherent patients. All models control
orbidity Index scores.
Table 3 Adjusted health care costs during 12-month period following 5-ASA initiation, by 5-ASA adherence status











Cost of inpatient admissions $14,541.65 [$14,313.80, $14,769.49] $28,726.65 [$28,443.11, $29,010.19] <0.0001
Cost of ER visits $495.33 [$477.91, $512.76] $635.95 [$621.95, $649.94] <0.0001
Cost of outpatient office visits $1,081.83 [$1,046.79, $1,116.87] $1,145.67 [$1,121.99, $1,169.35] 0.0031
Cost of other outpatient/ ancillary visits $3,702.39 [$3,602.08, $3,802.70] $4,923.29 [$4,837.67, $5,008.91] <0.0001
Cost of pharmacy prescriptions $5,309.84 [$5,180.82, $5,438.86] $3,189.88 [$3,142.40, $3,237.35] <0.0001
Cost of UC-related pharmacy prescriptions $3,568.57 [$3,519.87, $3,617.27] $1,718.20 [$1,702.68, $1,733.73] <0.0001
Cost of non–UC-related pharmacy prescriptions $1,845.51 [$1,746.93, $1,944.09] $1,541.60 [$1,487.04, $1,596.17] <0.0001
Cost of non-pharmacy visits $8,101.24 [$7,848.17, $8,354.30] $14,226.32 [$13,936.79, $14,515.85] <0.0001
Cost of total visits $13,464.89 [$13,094.43, $13,835.35] $17,339.36 [$17,033.28, $17,645.45] <0.0001
5-ASA = 5-aminosalicylate; ER = emergency department; UC = ulcerative colitis.
aPredicted costs are based on generalized linear models and control for age, gender, geographic region, health plan type, payer type, and Charlson Comorbidity
Index scores. Separate models were run for each cost sector; therefore, the mean predicted cost for each sector does not sum up to the total predicted cost.
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29% higher for nonadherent patients than for adherent
patients (mean [95% CI]: $17,339 [$17,033, $17,645] vs.
$13,465 [$13,094, $13,835]). It must be noted that al-
though GLM is a widely used tool to estimated adjusted
costs, the predicted cost estimates for any particular
cost sector were based on patients with at least one visit
in that sector. For example, the mean predicted in-
patient costs for the patient cohort were calculated
among those patients who had an inpatient visit. This
resulted in the mean inpatient costs for patients being
much higher than the overall costs for all visits.
Discussion
In this study, we examined the association between ad-
herence to 5-ASA therapy and overall health care
utilization and costs among patients with active UC. We
estimated that only 28% of the UC patients on 5-ASAs
who were included in the study were adherent to treat-
ment. This finding was consistent with previous studies
that have found adherence with 5-ASAs to be fairly low
(range: 15%[12] to 22%[13]). We also found that adher-
ence to oral 5-ASAs generally appeared to be associated
with decreased health care utilization and costs, espe-
cially the rate of inpatient and ER admissions, despite
the fact that adherent patients, on average, had higher
baseline CCI scores. One might expect that patients with
higher baseline CCI scores would be more likely to have
higher medical utilization and costs. However, in our
study, baseline CCI scores were higher in the adherent
patients, giving credence to the theory that 5-ASA ad-
herence may decrease utilization and costs despite the
higher baseline CCI scores. Patients therefore were likely
to benefit (i.e., have lower medical resource utilization)from adhering to their medication, regardless of their
prior overall medical condition. Our study thus corro-
borates the findings of Kane[14] that nonadherence
leads to higher cost of care. Increased medication costs
among the adherent patients were more than offset by
significant reductions in other cost sectors, such as
inpatient costs, ER admission costs, outpatient physician
and other visits, and nonpharmacy visit costs. Our
results were consistent with the American Gastroentero-
logical Association’s report on the burden of gastrointes-
tinal diseases, which found pharmacy and inpatient costs
to be the key cost driver in the overall burden of UC [2].
While our data source presents unique advantages in
assessing medication adherence and associated out-
comes, our study is subject to several limitations inher-
ent in most analyses of retrospective claims data.
Therapy may be interrupted for clinically appropriate
reasons, such as side effects associated with 5-ASAs and
abnormal laboratory results. If this occurred, the calcu-
lated MPR would underestimate actual adherence rates.
We also assumed complete medication ingestion, but
patients may have disposed of medication prior to refill
or stockpiled medication for future use [29]. This would
cause the MPR to overestimate actual adherence. Finally,
some of the defined UC-related prescriptions could
have been used for other indications. Despite these lim-
itations, administrative claims data remain a reliable and
well-accepted source for estimating adherence with
chronic-use medications by using validated measures,
such as the MPR [18,19,29,30]. Second, all UC patients
were identified as such through the analysis of ICD-9-
CM diagnosis codes that, if recorded inaccurately, may
have caused some patients to be misclassified into the
defined groups. The accuracy of our results therefore
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Link database. The impact of misclassification bias stem-
ming from analyses of claims data has been described
in previous research [31,32]. Third, in order to select
patients with active UC, we required that patients have
least one corticosteroid prescription in the 12-month
period following 5-ASA initiation. A possible confounder
is that some patients might have stopped their 5-ASA
therapy due to non-response or because they are more
severe patients and moved on to corticosteroids, thereby
appearing to be nonadherent to 5-ASAs, not because of
nonadherent medication-taking behavior but for a clinic-
ally appropriate reason. If this hypothesis was true,
we would expect corticosteroid use to be greater in the
non-adherent group. We therefore examined the total
number of prescriptions for corticosteroids over the 12-
month follow-up period for the adherent and non-
adherent groups and found the reverse to be true: the
adherent group had more steroid prescriptions on aver-
age (4.1) compared to the non-adherent group (3.4),
and stayed on steroids for a longer duration (88.6 vs.
67.9 days). This demonstrates that these patients are
more adherent in general and are therefore more adher-
ent to their corticosteroid prescriptions too. Therefore, it
seems evident that higher severity, as measured by
theuse of corticosteroids in the non-adherent group is
not an explanation for lower 5-ASA adherence in that
group. Fourth, we did not have any data on important
clinical factors such as treatment-related adverse events
or disease severity, or demographic factors such as race
and socioeconomic status, any of which could impact
both medication adherence and health care resource
utilization. We did however find no significant difference
in the proportion of patients using other 5-ASA drugs
such as immunosuppressants and antibiotics between
the two study groups, indicating that the groups had
similar disease severity. Fifth, our study did not control
for pre-index resource utilization. It is possible that non-
adherent patients had greater costs prior to 5-ASA initi-
ation. Finally, our study focused only on direct all-cause
costs to commercial third-party payers, and is not repre-
sentative of other health care payers such as Medicare or
Medicaid. Also, there are other indirect costs, such as
lost wages and reduced workplace productivity, which
must be assessed in order to gain an understanding of
the complete societal impact of UC.
Conclusions
In conclusion, this study finds adherence to oral 5-ASAs
to be suboptimal and that patients who are nonadher-
ent to therapy have greater health care costs. Efforts
to promote oral 5-ASA adherence in patients with UC
may lead to cost-savings for third-party payers and
other stakeholders.Endnotes
aAt the request of the health services with which we
worked, we have been asked to use this term to refer to
our informants in order to ensure anonymity.
Competing interests
Debanjali Mitra and Keith L. Davis are employees of RTI Health Solutions, an
independent contract research organization that received research funding
from Shire for this study. Dr. Paul Hodgkins and Linnette Yen are employees
of Shire and own stock in the company. Dr. Russell D. Cohen is employed at
the University of Chicago Medical Center and serves as a consultant to Shire.
The author(s) declare that they have no other competing interests.
Authors’ contributions
Debanjali Mitra, Dr. Paul Hodgkins, and Linnette Yen were the primary
developers of the study design and contributed to analysis and
interpretation of results as well to the development of this manuscript. As
principal investigator, Debanjali Mitra had full access to all the data in the
study and takes responsibility for the integrity of the data and the accuracy
of the data analysis. Debanjali Mitra and Keith L. Davis led all statistical
analyses. Debanjali Mitra also served as the primary writer in drafting the
manuscript text and in interpreting the results. Dr. Russell D. Cohen provided
medical and clinical advice to refine and validate the study, and he
participated in the drafting of the manuscript. All authors read and approved
the final manuscript.
Acknowledgements
Funding for this study was provided by Shire Development, Inc.
The publication of this study’s results is not contingent on the sponsor’s
approval or censorship of the manuscript.
Author details
1RTI Health Solutions, 3040 Cornwallis Road, Post Office Box 12194, Research
Triangle Park, NC 27709-2194, USA. 2Shire Development Inc, 725
Chesterbrook Boulevard, Chesterbrook, PA 19087, USA. 3The University of
Chicago Medical Center, 5841 South Maryland Avenue, Chicago, IL 60637,
USA.
Received: 6 December 2011 Accepted: 20 September 2012
Published: 24 September 2012
References
1. Loftus EV, Silverstein MD, Sandborn WJ, Tremaine W, Harmsen W,
Zinsmeister A: Ulcerative colitis in Olmstead county, Minnesota,
1940–1993: incidence, prevalence, and survival. Gut 2000, 46:336–343.
2. American Gastroenterological Association: The burden of gastrointestinal
diseases. 2001, www.lewin.com/content/publications/2695.pdf.
3. Kappelman MD, Rifas-Shiman SL, Porter CQ, Ollendorf DA, Sandler RS,
Galanko JA, Finkelstein JA: Direct health care costs of treatment of
Crohn’s disease and ulcerative colitis in U.S. Children and adults.
Gastroenterology 2008, 135:1907–1913.
4. Bickston SJ, Waters HC, Dabbous O, Tang BI, Rahman M: Administrative
claims analysis of all-cause annual costs of care and resource utilization
by age category for ulcerative colitis patients. J Manag Care Pharm 2008,
14(4):352–362.
5. Sutherland L, Roth D, Beck P, May G, Makiyama K: Oral 5-aminosalicylic
acid for maintenance of remission in ulcerative colitis. Cochrane Database
Syst Rev 2006, 2:CD000544.
6. Sutherland L, MacDonald JK: Oral 5-aminosalicylic acid for induction of
remission in ulcerative colitis. Cochrane Database Syst Rev 2006, 3:
CD000543.
7. Kornbluth A, Sachar DB: Practice parameters committee of the American
college of gastroenterology: ulcerative colitis practice guidelines in
adults: American college of gastroenterology, practice parameters
committee. Am J Gastroenterol 2010, 105:501–523.
8. Gordis L: Conceptual and methodologic problems in measuring patient
compliance. In Compliance in health care. Edited by Haynes RB, Sackett DL.
Baltimore: Johns Hopkins University Press; 1979.
9. Haynes RB, Dantes R: Patient compliance and the conduct and
interpretation of therapeutic trials. Control Clin Trials 1987, 8:12–19.
Mitra et al. BMC Gastroenterology 2012, 12:132 Page 10 of 10
http://www.biomedcentral.com/1471-230X/12/13210. Kennedy S, McIntyre R, Fallu A, Lam R: Pharmacotherapy to sustain the
fully remitted state. J Psychiatry Neurosci 2002, 27(4):269–280.
11. Breen R, Thornhill JT: Noncompliance adherence with medication for
psychiatric disorders. CNS Drugs 1998, 9:457–471.
12. Yen L, Klingman D, Hodgkins P: Improved adherence and persistence with
once-daily lialdaW therapy for ulcerative colitis in the united states:
retrospective analysis of a Multiplan claims database, Poster presented at
American college of gastroenterology annual scientific meeting. San
Antonio, Texas; 2010:18–20.
13. Shaya FT, El Khoury AC, Wong W, Whitelaw N, Whitelaw G, Joseph RE,
Cohen RD: Persistence with pharmacotherapy for gastrointestinal
disease: associated costs of health care. P&T 2006, 31:657–665.
14. Kane SV: Systematic review: adherence issues in the treatment of
ulcerative colitis. Aliment Pharmacol Ther 2006, 23:577–585.
15. IMS LifeLink data on file: LifeLink health plan claims database overview and
study design issues; 2010. http://www.uams.edu/TRI/hsrcore/
Lifelink_Health_Plan_Claims_Data_DesignIssues_wcost_April2010[1].pdf.
16. Charlson ME, Pompei P, Ales KL, McKenzie CR: A new method of
classifying prognostic co-morbidity in longitudinal studies: development
and validation. J Chron Dis 1987, 40:373–383.
17. Deyo RA, Cherkin DC, Ciol MA: Adapting a clinical co-morbidity index for
use with ICD-9-CM administrative databases. J Clin Epidemiol 1992,
45:613–619.
18. Andrade SE, Kahler KH, Frech MPH, Chan KA: Methods for evaluation of
medication adherence and persistence using automated databases.
Pharmacoepidemiol Drug Saf 2006, 15:565–574.
19. Karve S, Cleves MA, Helm M, Hudson TJ, West DS, Martin BC: Good and
poor adherence: optimal cut-point for adherence measures using
administrative claims data. Curr Med Res Opin 2009, 25(9):2303–2310.
20. Grosset KA, Bone I, Grosset DG: Suboptimal medication adherence in
Parkinson’s disease. Mov Disord 2005, 20(11):1502–1507.
21. Rosen MI, Rigsby MO, Salahi JT, Ryan CE, Cramer JA: Electronic monitoring
and counseling to improve medication adherence. Behav Res Ther 2004,
42:409–422.
22. George CF, Peveler RC, Heiliger S, Thompson C: Compliance with tricyclic
antidepressants: the value of four different methods of assessment. Br J
Clin Pharmacol 2004, 50:166–171.
23. US Department of Labor, Bureau of Labor Statistics: Consumer price index—
all urban consumers (current series). 2011. http://data.bls.gov/PDQ/outside.
jsp?survey=cu.
24. Basu A, Manning WG: Issues for the next generation of health care cost
analyses. Med Care 2009, 47(7 Suppl 1):S109–S114.
25. Fu AZ, Qiu Y, Radican L, Wells BJ: Health care and productivity costs
associated with diabetic patients with macrovascular comorbid
conditions. Diabetes Care 2009, 32(12):2187–2192. E-pub 2009 Sep 3.
26. Wedderburn RWM: Quasi-likelihood functions, generalized linear models,
and the gauss-Newton method. Biometrika 1974, 61:439–447.
27. Manning WG: The logged dependent variable, heteroscedasticity, and
the retransformation problem. J Health Econ 1998, 17:283–295.
28. Manning WG, Mullahy J: Estimating log models: to transform or not to
transform? J Health Econ 2001, 20:461–494.
29. Sikka R, Xia F, Aubert RE: Estimating medication persistency using
administrative claims data. Am J Manag Care 2005, 11(7):449–457.
30. Karve S, Cleves MA, Helm M, Hudson TJ, West DS, Martin BC: Prospective
validation of eight different adherence measures for use with
administrative claims data among patients with schizophrenia. Value
Health 2009, 12(6):989–995.
31. Newcomer R, Clay T, Luxenberg JS, Miller RH: Misclassification and
selection bias when identifying Alzheimer’s disease solely from Medicare
claims records. J Am Geriatr Soc 1999, 47(2):215–219.
32. Losina E, Barrett J, Baron JA, Katz JN: Accuracy of medicare claims data for
rheumatologic diagnoses in total hip replacement recipients. J Clin
Epidemiol 2003, 56:515–519.
doi:10.1186/1471-230X-12-132
Cite this article as: Mitra et al.: Association between oral 5-ASA
adherence and health care utilization and costs among patients with
active ulcerative colitis. BMC Gastroenterology 2012 12:132.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
